Atritech
Founded Year
2000Stage
Unattributed | AliveTotal Raised
$91.82MValuation
$0000Last Raised
$30M | 15 yrs agoAbout Atritech
Atritech has developed the WATCHMAN, an implantable device designed to capture clots that may form in the left atrial appendage of patients with atrial fibrillation, thereby aiming to reduce the risk of stroke and eliminating the need for long-term use of blood thinning medications.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Atritech Patents
Atritech has filed 53 patents.
The 3 most popular patent topics include:
- Cardiac anatomy
- Cardiac arrhythmia
- Cardiac electrophysiology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/24/2017 | 1/26/2021 | Cardiac anatomy, Cardiac arrhythmia, Cardiac surgery, Cardiology, Cardiac electrophysiology | Grant |
Application Date | 11/24/2017 |
|---|---|
Grant Date | 1/26/2021 |
Title | |
Related Topics | Cardiac anatomy, Cardiac arrhythmia, Cardiac surgery, Cardiology, Cardiac electrophysiology |
Status | Grant |
Latest Atritech News
May 18, 2011
Paul Pisklak Cardiac Surgery , Cardiology We last reported on the Watchman left atrial appendage device back in 2009. Since then, Minnesota based AtriTech has been acquired by Boston Scientific, and there is new data about its use as an alternative to warfarin. To review, the Watchman is a device that is placed in the left atrium to exclude the left atrial appendage, where a thrombus is likely to form in a patient with atrial fibrillation, thus reducing the potential for a stroke. The device is implanted in the cath lab with conscious sedation ( see animation ). Previous studies have confirmed the non-inferiority of this device to warfrain, and the latest data shows its utility in patients who have contraindications to warfarin. Twenty-four of these patients were implanted with the Watchman device and received aspirin and Plavix, and no cerebrovascular events or device dislodgements were noted (follow-up time averaged 4.2 months). There was one case of a device-related thrombus that resolved with heparin therapy. Although larger studies and more follow-up time is needed, this device seems to be an option for people who are unable to take warfarin. The Watchman remains in investigational status in the United States at this time.
Atritech Frequently Asked Questions (FAQ)
When was Atritech founded?
Atritech was founded in 2000.
Where is Atritech's headquarters?
Atritech's headquarters is located at 3750 Annapolis Lane, Plymouth.
What is Atritech's latest funding round?
Atritech's latest funding round is Unattributed.
How much did Atritech raise?
Atritech raised a total of $91.82M.
Who are the investors of Atritech?
Investors of Atritech include Affinity Capital Management, Tullis Health Investors, Split Rock Partners, Prism VentureWorks, Vector Capital and 9 more.
Who are Atritech's competitors?
Competitors of Atritech include Velico Medical, ALung Technologies, Lucina Health, Salutaris Medical Devices, Infrascan, Penumbra, Samsara Vision, Apnex Medical, Concentric Medical, Micrus Endovascular and 23 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Atritech to Competitors
MetaCure is a clinical-stage device company focused on the treatment of adult type II diabetes via an implantable pulse generator delivering electrical stimulation via gastric contractility modulation.
Windy Hill Medical is a medical device and pharmaceutical company focused on the development of products to reduce the risk of developing breast cancer in patients deemed to be at high risk.
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation, and is proven to resolve and restore normal mitral valve function. It was formerly known as mValve. The company was founded in 2007 and is based in St. Louis Park, Minnesota.
ThermalTherapeutic Systems is currently developing a portable next-generation perfusion device for international distribution.
NeuroDx addresses important unmet needs in the neurosurgical market. Their lead product, ShuntCheck, is an aid to the detection offlow in implanted cerebrospinal fluid (CSF) shunts.
Salutaris Medical Devices (SalutarisMD) is a clinical-stage medical device company developing an investigational ophthalmic treatment for Wet Age-related Macular Degeneration (Wet AMD). SalutarisMD is developing a minimally invasive procedure that can be performed in an outpatient or physician office setting in approximately 15 minutes.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
